Welcome to our dedicated page for Masimo SEC filings (Ticker: MASI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Masimo Corporation’s SEC filings document material-event disclosures for a medical technology company focused on noninvasive patient monitoring, hospital automation, connectivity and remote monitoring. The filing record includes Form 8-K reports for operating and financial results, Regulation FD materials, exhibits, material agreements, shareholder voting matters, governance matters, capital-structure disclosure and clinical or regulatory disclosure categories.
The company’s filings also document completed corporate actions, including the disposition of the Sound United consumer audio business and related pro forma financial information. Transaction-related filings cover formal agreements, proxy and voting materials, litigation-related disclosures, risk language and other public-company reporting items without changing the company’s healthcare technology identity.
Masimo Corporation's EVP and General Counsel, Charles Dadswell, reported two dispositions of restricted stock units on June 10, 2026, each coded as a disposition to the issuer. The transactions covered 10,261 and 11,886 Masimo RSUs, both tied to unvested awards granted in October 2025 and March 2026.
That same day, Masimo completed a merger in which Mobius Merger Sub was combined with Masimo, making Masimo a wholly owned subsidiary of Danaher Corporation. At the effective time of the merger, most Masimo RSUs were assumed by Danaher and converted into Danaher RSUs using a formula based on a $180.00 per-share merger price and a $183.33 volume‑weighted average trading price for Danaher stock.
Masimo Corporation’s Chief Marketing Officer Tim Benner reported the disposition of multiple equity awards to the issuer in connection with Masimo’s merger into a subsidiary of Danaher Corporation on June 10, 2026. The Form 4 shows 3,490 performance-based RSUs, 2,537 non-qualified stock options, and two blocks of 6,128 and 1,163 time-based RSUs, all tied to Masimo common stock.
At the merger’s effective time, Masimo RSUs were assumed by Danaher and converted into Danaher RSUs using a value of $180.00 per Masimo share and a Danaher ten-day volume‑weighted average price of $183.33 per share. Outstanding Masimo stock options and performance-based RSUs were canceled and converted into cash rights based on $180.00 per underlying share, less any applicable tax withholding. Following these transactions, the affected Masimo derivative awards show zero remaining balance on this filing.
Masimo Corporation’s EVP and Chief Financial Officer Micah W. Young disposed of all remaining Masimo equity interests on June 10, 2026, in connection with the company’s merger into a wholly owned subsidiary of Danaher Corporation. At the merger’s effective time, each Masimo common share was canceled and converted into the right to receive $180.00 per share in cash, and Young’s 25,656 common shares were reported as a disposition to the issuer. Outstanding performance-based restricted stock units were canceled and converted into the right to receive $180.00 per underlying share in cash, while other restricted stock units were assumed by Danaher and converted into Danaher RSUs based on a ratio using the $180.00 merger price and Danaher’s $183.33 ten-day volume-weighted average price. All Masimo stock options were canceled and converted into cash equal to the excess of the $180.00 merger price over their exercise prices, and the Form 4 shows Young holding zero Masimo shares or derivatives following these transactions.
MASIMO CORP reports that its merger with Danaher closed on June 10, 2026, with Masimo becoming a wholly owned subsidiary of Danaher. Each share of Masimo common stock was canceled and converted into the right to receive $180.00 per share in cash at the effective time of the merger.
Chief Executive Officer Catherine M. Szyman reported dispositions to the issuer of 7,605 shares of common stock and multiple equity awards, all coded as issuer dispositions rather than market sales. Unvested restricted stock units were assumed by Danaher and converted into Danaher RSUs using the $180.00 merger price and a Danaher volume-weighted average price of $183.33. Outstanding stock options and performance-based RSUs were canceled and converted into cash based on the $180.00 merger consideration, leaving Szyman with no remaining Masimo equity holdings in this filing.
Masimo Corporation completed its merger on June 10, 2026, cashing out all common shareholders. At the merger’s effective time, each share of Masimo common stock was cancelled and converted into the right to receive $180.00 in cash per share, before taxes.
The reporting group led by Politan Capital Management held 4,590,873 shares, which were converted into the cash merger consideration, and Quentin Koffey’s 1,119 restricted share units were also cancelled for the same per‑share cash amount. Following this transaction, all reporting persons now report 0 shares and 0.0% beneficial ownership of Masimo, with no remaining voting or dispositive power.
Masimo Corporation deregisters all unsold securities registered on its Form S-3 following the completion of a merger with Danaher Corporation.
The post-effective amendment states that, pursuant to the Agreement and Plan of Merger dated February 16, 2026, Merger Sub merged with and into Masimo on June 10, 2026, the registrant became a wholly owned subsidiary of Danaher, and all offerings under Registration No. 333-285240 have been terminated and removed from registration.
Masimo Corporation has completed its acquisition by Danaher Corporation. At the merger’s effective time, each outstanding Masimo common share (with certain limited exceptions) was cancelled and converted into the right to receive $180.00 in cash per share, without interest.
Masimo is now a wholly owned subsidiary of Danaher, which funded the transaction with cash on hand. In connection with closing, Masimo repaid in full and terminated its December 1, 2025 Credit Agreement, and all related guarantees were released.
Masimo’s common stock ceased trading on Nasdaq before the market opened on the closing date and will be delisted and deregistered following the filing of Form 25 and Form 15. All prior stockholder rights ended, other than the right to receive the cash merger consideration. Masimo’s pre-closing directors resigned, a Danaher designee became director of the surviving corporation, and most officers continued in their roles. Certain executives entered into separation and short-term consulting agreements and will receive previously arranged change-in-control severance benefits.
Masimo Corp notified Nasdaq of the removal of its Common Stock from listing and/or registration on the Nasdaq Stock Market. The exchange certified compliance with 17 CFR 240.12d2-2 procedures and the issuer certified compliance with the exchange's rules for voluntary withdrawal.
Masimo Corp. Schedule 13G: Pentwater Capital Management reports beneficial ownership of 3,176,000 shares of Common Stock, representing 6.1% of the class. The percentage is calculated on 52,362,808 shares outstanding as of March 31, 2026, as reported in a Form 8-K cited in the filing.
The shares are held by the Pentwater Funds with shared voting and dispositive power reported; Matthew Halbower is disclosed as the sole shareholder of the investment manager's general partner and joined the joint filing.
Barclays PLC reports beneficial ownership of 2,892,262 shares of Masimo Corp common stock, representing 5.54% of the class as of 03/31/2026.
The filing (Schedule 13G) lists Barclays' sole voting and dispositive power over the reported shares. The report names Barclays Bank PLC, Barclays Capital Inc., Barclays Capital Securities Ltd. and Barclays Investment Solutions Limited as relevant subsidiaries. The form is signed by a Barclays director on 05/14/2026.